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ABSTRACT  
  
Objective: The objective of this selective EBM review is to determine whether or not ipilimumab 
is an effective treatment in patients diagnosed with metastatic melanoma.  
  
Study Design: Review of three English primary studies published between 2009 and 2010.   
  
Data Sources: Randomized, controlled, double-blind clinical studies comparing ipilimumab +/-
gp100 peptide to a placebo +/- gp100.  Studies were found using PubMed and Cochrane 
databases.  
  
Outcomes Measured: Each of the studies measured outcomes of disease progression and overall 
survival.  Response rate to treatment was also measured in two studies. Measurement of these 
outcomes was achieved utilizing the following classifications systems:  [TNM] categorization, & 
Kaplan-Meier product-limit method of determining survival rates.  
  
Results: In the Hodi et al. study the median overall survival was greater among patients receiving 
ipilimumab plus glycoprotein100 (gp100), as compared to patients receiving gp100 alone.  In the 
Weber et al. study the median overall response rates were higher for those receiving ipilimumab 
10 mg/kg alone, in comparison to ipilimumab 10 mg/kg with budesonide (blind).  Subjects with 
more severe irAEs (immune related adverse events) experienced better disease control compared 
to those with less serious irAEs.  A dose-dependent relationship was illustrated in the Wolchok et 
al. study; best overall response rate was notably higher for those receiving a higher dose of 
ipilimumab, opposed to a lower dose.  
 
Conclusion: The results of all three of the reviewed RCT’s and randomized double-blind studies  
demonstrated that ipilimumab shows activity in advanced melanoma.  According to Hodi et al., 
ipilimumab may improve overall survival.   The study done by Wolchock et al. provides 
evidence of a dose-dependent relationship on efficacy of ipilimumab, along with irAEs.  In terms 
of safety, it was reported that most adverse events were manageable if not reversible with 
appropriate treatment, although serious & life-threatening effects were possible.  Continued 
research is needed to determine the optimal dosing and regimen for reducing adverse effects and 
maximizing efficacy.  Further research is desired, particularly at a dose of 10 mg/kg. 
 
  
Key Words: melanoma, metastatic, skin cancer, treatment, ipilimumab, immunotherapy, CTL 
antigen-4  
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INTRODUCTION  
 Skin cancer is the most common cancer in the United States, United Kingdom, and 
Australia.1 Melanoma, by far, accounts for the greatest number of deaths due to skin disease. 2      
In 2009, “58,094 cases of melanoma were diagnosed in the United States”, with 33,041 of those 
men and 25,053 cases in women.  Melanoma makes up approximately 5% of all cancers.  
Tragically, one in four cases of melanoma occurs before the age of 40.  There were a staggering 
8,461 deaths in the U.S. in 2009 from melanoma alone.  Metastatic melanoma, meaning the 
spread of cancer from the primary site to other areas of the body, occurs in 15–26% of stage I 
and stage II melanoma.   The single most important prognostic factor is depth of tumor.  Tumor 
thickness in millimeters, <1mm,  2–4 mm, and > 4 mm dictate ten year survival rates of 95%, 
55%, and 30%, respectively (Figure 1).   In the case of distant metastases, 5-year survival 
actually plummets to even less than 10%.¹ 1 According to the American Joint Committee on 
Cancer stage IV, the median survival of patients with melanoma who have distant metastases is 
less than 1 year. 3 
                              
 
Figure 1. Survival rates of melanoma -- related to tumor thickness in millimeters ¹ 
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 The current treatment modality for melanoma is largely surgical excision with safety 
margins dictated by stage and tumor thickness, possibly including lymph node dissection.  
Metastatic melanoma, on the other hand, is essentially untreatable.   No treatment is approved 
beyond the first-line therapy for metastatic melanoma.  The standard of care being enrollment in 
a clinical trial. 3 Medical management of distant metastases is considered palliative, at best, 
considering the high incurability rate.¹  Unfortunately, melanoma often spreads to distant sites 
initially, including lymph nodes, skin and subcutaneous tissues.   Palliative care consists of 
chemotherapeutic agents, radiation, and possibly a clinical trial medication.  Dacarbazine is 
generally accepted as the most effective monotherapeutic agent.  A chemotherapeutic treatment 
of stage IV melanoma that has been found disappointing, showing only a <20% response rate 
and absolutely no influence on overall survival. 2  The amount of resources required and costs of 
treatment increase considerably after evolution of metastases in individuals with melanoma.  
Mean health care costs increased from $22,260 at baseline to $113,940 per patient a year (p-
value <0.01). 4  These statistics should be both relevant and concerning to the Physician 
Assistant (PA) professional, as accepted members of healthcare teams, PA’s are working in 
specialties, inclusive of dermatology and surgery.  Despite these exorbitant costs, up until this 
point, no treatment has proved effective in preventing or arresting progression of the disease.  
 Ipilimumab, also known as MDX-010 or MDX-101, is a human monoclonal antibody 
that blocks cytotoxic T-lymphocyte antigen 4.  It is intended to be used as a drug to activate the 
immune system. Classified as a vaccine, ipilimumab works with the immune system to boost the 
body’s response against melanoma cells.  The mechanism of action to explain the drugs function 
is through blocking the negative feedback on T-cells, it  more to attack melanoma cells.   This 
type of immune therapy is the latest in attempts to halt progression of metastatic melanoma in 
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hopes of improving prognosis.  Increasing overall survival among patients with metastatic 
melanoma has been an evasive goal.   No therapy has proven effective in a phase 3, randomized, 
controlled trial to improve overall survival in individuals diagnosed with metastatic melanoma. ³  
Ipilimumab is showing promising potential in this area. The precise efficacy and safety of 
ipilimumab in patients with advanced melanoma are not widely known. ² 
OBJECTIVE 
 The objective of this systematic review is to determine whether or not ipilimumab is an 
effective treatment in patients diagnosed with metastatic melanoma.    
METHODS  
 All three randomized, double-blind studies selected met the criteria for subjects who were 
at least 16 years old with a medical diagnosis of unresectable stage III or IV melanoma, who had 
received prior treatment.3,5,6 Two of the three studies limited the population to only 18 years and 
older. 3,5  Criteria for exclusion for participation in the study were concomitant treatment, or less 
than a four year life expectancy.   
 Interventions included ipilimumab 3 mg/kg or 10 mg/kg compared to a control with or 
without glycoprotein 100 (gp100). 3,5,6  In the Hodi et al study,  the treatment groups receiving 
ipilimumab at a dose of 3 mg per kilogram alone & those receiving ipilumumab with gp100 
peptide vaccine were compared to a control group receiving a placebo with gp100.   Treatment 
was administered once every 3 weeks for up to four treatments. 3  The Weber et al. study 
compared ipilimumab 10 mg/kg with budesonide to a control (ipilimumab 10 mg/kg), 
administered once every 3 weeks for four doses. 5  In the crossover study by Wolchok  et al., 
ipilimumab was compared at different doses, 10 mg/kg and 3 mg/kg, administered intravenously 
once every 3 weeks for four cycles followed by maintenance therapy every 3 months. 6  
Outcomes of interest included survival rate, progression of disease, and adverse events. 
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 A detailed search for the studies was conducted December 2010 to February 2011 with the 
key words, “melanoma”, “metastatic”, “skin cancer”, “treatment”, “ipilimumab”,  
“immunotherapy”, and “CTL antigen-4”.  The Cochrane Library and PubMed (U.S. National 
Library of Medicine) databases were utilized.  Only English language articles published in peer-
reviewed journals were selected.  Articles were subsequently narrowed according to relevance 
and outcomes pertinent to patients.  Inclusion criteria for the selection of articles involved  
randomized, controlled, published after 2009, and having patient oriented evidence which 
matters (POEMS). The only exclusion criteria were if they were published before 2007, due to a 
pre-existing meta-analysis reported at that time.  The statistics reported included 95% confidence 
interval.  The Wolchok et al study reported a p-value <0.05 being statistically significant. 6  P-
values for other studies were not statistically significant.  Studies were evaluated for relative risk 
reduction (RRR), absolute risk reduction (ARR), and numbers needed to treat (NNT).  
Demographics of the final studies selections are presented in Table 1. 3,5,6 
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Table 1: Demographics of included studies 3,5,6 
Study Type # 
pts 
Age Inclusion Exclusion W/D Intervention 
Hodi 
2010 3 
Randomized 
double-
blind, phase 
III study 
 
403; 
137 
>18 yo Patients at least 18 
yo; diagnosis of 
unresectable stage 
III or IV melanoma 
& received a 
previous therapy 
containing:dacarbaz
ine, temozolomide, 
fotemustine, 
carboplatin, or 
interleukin-2; 
positive HLA-
A*0201; normal 
hematoloic, hepatic, 
& renal fx; no 
systemic tx in the 
last 28 days; Life 
expectancy of at 
   
  
   
 
 
<18 yo; primary 
ocular melanoma 
Any cancer patient 
is disease-free for 
less than 5 years; 
previous  anti-
CTLA-4 antibody or 
cancer vaccine; 
autoimmune 
disease; pregnant; 
concomitant tx with 
any nonstudy 
anticancer therapy 
or 
immunosuppressive 
agent; long-term of 
systemic 
corticosteroids 
 
 
 
 
 
 
380;1
31 
Randomized 
to receive  
ipilimumab 3 
mg/kg of body 
weight plus 
gp100 peptide 
vaccine; 
ipilimumab 
plus gp100 
placebo 
-administered 
QD every 3 
weeks for 4 
treatments  
 
Weber 
2009 5 
Randomized 
double-
blind, 
placebo-
controlled, 
multicentre, 
phase II trial 
 
115 >18 yo Patients at least 18 
yo; histological 
diagnosis of 
unresectable & 
measurable stage III 
or IV melanoma; 
previous systemic 
therapy or 
untreated; Life 
expectancy atleast 4 
months;ECOG 
performance status 
of 0-1 
 
 
 
 
<18 yo, ocular 
melanoma; Active 
untreated CNS 
metastases; 
malignancies had 
been disease-free for 
<5 years; 
Autoimmune 
disease; 
investigational drugs 
within 4 weeks; 
Previous tx with an 
anti-CTLA-4 
antibody; 
immunosuppressive 
 
 
 
 
 
N/A Randomized 
to receive 
ipilimumab 10 
mg/kg  with 
daily blinded 
budesonide 
-administered 
every 3 weeks 
for four doses  
 
Wolch-
ok 
2010 6 
 
Randomized
double-
blind, 
multicentre 
parallel 
group study 
 
217 >16 yo Patients at least 16 
yo; histological 
diagnosis of 
unresectable & 
measurable stage III 
or IV melanoma; 
atleast 1 previous tx 
with antitumor 
regimen; progressed 
or failed response 
within 12 weeks or 
unable to tolerate 
regimen 
<16 yo 3 Randomized 
to receive 
ipilimumab 10 
mg/kg  
–administered 
every 3 weeks 
for 4 cycles 
(induction) 
followed by 
maintenance 
every 3 mo. 
 
Hansen, Ipilimumab and Melanoma 6 
OUTCOMES MEASURED 
 The outcomes measured to determine response to therapy were survival rate and 
progression of disease.  Methods employed to measure such outcomes were the WHO criteria in 
assessing lesions, the Tumor-Node-Metastasis [TNM] categorization for melanoma & Kaplan-
Meier product-limit method. 3,5,6 
 Each of the three studies measured outcomes of disease progression and overall survival.  
Response rate to treatment was also measured in two of the three studies, the Weber et al. study 
& Wolchok et al. study.  All three studies applied the WHO criteria to ascertain overall response 
according to combined assessments of index & non-index lesions and the Kaplan-Meier product-
limit method of determining survival rates.  Measurement of outcomes in the Hodi et al study 
were also achieved utilizing the Tumor-Node-Metastasis [TNM] categorization of the American 
Joint Committee on Cancer, classification system. 3,5,6 
 In addition, the Wolchok et al. study incorporated imaging in the form of CT or MRI, 
documenting a baseline which was compared at each tumor assessment.  Cutaneous lesions were 
evaluated and recorded with digital photography.  The primary objective in this study was 
overall response rate, simply defined by the proportion of patients with complete or partial 
responses according to the World Health Organization (WHO) criteria.  Secondary objectives 
analyzing progression of the disease included: disease control rate and median overall survival. 6   
RESULTS 
 The results assessing the efficacy pertaining to the primary outcome were presented   
as dichotomous data in all three studies.  While 131 of participants in the experimental group 
withdrew from the Hodi et al. study, and 3 participants withdrew from the Wolchok et al. study, 
the efficacy analyses were presented as an intention to treat. 3,5,6  Hodi et al. demonstrated higher 
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rates of overall survival in the ipilimumab (experimental) group opposed to those receiving 
gp100 (control).  (Table 2). 3 
 
Table 2: Efficacy of Ipilimumab in Treatment of Advanced Melanoma - NNT 3,5,6 
Study experimental 
group (EER) 
control 
group 
(CER) 
p-value RRR ARR NNT 
Hodi, 2010  45.6% 43.6% NS 5% 2% 50 pts 
Weber, 2009  12.1% 15.8% NS 0.23% -3.7% -27 pts* 
Wolchok, 2010  11.1% 4.2% p=0.0015 1.6% 6.9% 15 pts 
RRR=Relative Risk Reduction    ARR=Absolute Risk Reduction    NNT=Numbers Need to 
Treat  
 * This negative value for NNT indicates that for every 27 patients treated with the 
 experimental treatment (ipilimumab budesonide), 1 patient fewer had improved disease 
 compared to the control.   
 NS =  p-value not significant for the dichotomous data presented in the study.  
 
The median overall survival was approximately 10 months among patients receiving ipilimumab 
with or without gp100, as compared with 6.4 months among patients receiving gp100 alone. 
Median overall survival proved greater among patients receiving ipilimumab plus 
glycoprotein100 (gp100), as compared to patients receiving gp100 alone.  A greater reduction in 
risk of progression was seen with ipilimumab alone as compared with gp100 alone. The highest 
percentage of patients with an objective response to treatment or disease which remained stable 
was in the ipilimumab-alone group, this group had a best overall response rate of 10.9%. 3 
 
 In the Weber et al. study the median overall response rates were higher for those 
receiving ipilimumab alone, in comparison to ipilimumab with budesonide (blind). The best 
overall response rates were 15.8% for those receiving ipilimumab, 12.1% receiving ipilimumab 
10 mg/kg with budesonide, median overall survival of 19.3 and 17.7 months, respectively (Table 
Hansen, Ipilimumab and Melanoma 8 
2).  Patients with grade 3 to 4 irAEs (immune-related adverse events), experienced better disease 
rates as compared to patients with grade 0 to 2 irAEs.  Even so, noteworthy clinical benefit was 
still experienced by many patients with grade 1 to 2 irAEs. 5 
 The Wolchok et al. study utilized a cross-over study to compare a range of ipilimumab 
doses.  The best overall response rates illustrated a dose-dependent relationship, “11.1% for 10 
mg/kg, 4.2%  for 3 mg/kg, and 0%  for 0.3 mg/kg” (Table 3). 6  Immune-related adverse events 
of any grade became apparent in, “50 of 71, 46 of 71, and 19 of 72 patients at doses of 10 mg/kg, 
3 mg/kg, and 0.3 mg/kg, respectively” (Table 4). 6 
Table 3: Efficacy of Ipilimumab as related to dosage 6 
Study Low dose            
(3 mg/kg) 
High dose         
(10 mg/kg) 
p-value CI 
Wolchok, 2010 4.2% (0.9–11.7) 11.1% (4.9–20.7) p=0.0015* 95% 
 *Statistically significant p-value reported.  P-values deemed significant if <0.05. 
 Two-sided 95% CI, 0.5 significance level was reported for Wolchok et al. study in 
 comparison of best overall response rate to low-dose vs. high does ipilimumab. 
 
Table 4: Incidences of Adverse Events as Related to Ipilimumab Dose 6 
Study Ipilimumab          
(0.3 mg/kg) 
Ipilimumab            
(3 mg/kg) 
Ipilimumab       
(10 mg/kg) 
Wolchok, 2010 26% 65% 70% 
  
Noteworthy,  is the positive correlation between increase in dose and seemingly efficacy; 
unfortunately this association comes with an increase in reported irAEs (Table 4).  The most 
common immune-related adverse event (irAE) was diarrhea.  Diarrhea was reported in as many 
as 31%, 35 %, 28% of the patients receiving ipilimumab for the studies Hodi et al., Weber et al., 
and Wolchok et al., respectively. 3,5,6 The majority experienced improvement of symptoms 
following administration of corticosteroids.  3 
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DISCUSSION 
 This selective EBM review of the Hodi, Weber, and Wolchok et al. studies sought to 
determine if ipilimumab is an effective treatment for metastatic melanoma.  Ipilimumab, trade 
name, Yervoy, is a human monoclonal antibody intended to stimulate the immune system.   The 
vaccine is administered as an intravenous infusion designed to interfere with activity of cytotoxic 
T-lymphocyte antigen 4.   Essentially, the drug blocks the negative feedback on T-cells, which 
ultimately promotes more of these immune cells to attack melanoma cells. 7  Common adverse 
events to ipilumumab include nausea, diarrhea, rash, and fatigue. 6  There is a black box warning 
in effect for ipilimumab due to serious and potentially life-threatening side-effects of the drug 
including colitis, hepatitis, toxic epidermal necrolysis. 7  Ipilimumab shows an association with 
stimulation of  immune response against advanced melanoma. 3,5,6  This radical form of immune 
therapy is the latest in attempts at preventing progression of metastatic or advanced melanoma.  
 The Hodi et al. study itself was designed to examine the role of gp100 in conjunction 
with ipilimumab.  No additional therapeutic benefit was ascertained with inclusion of gp100.  
Although no difference in overall survival was detected between the experimental (ipilimumab) 
and control (ipilimumab plus gp100) groups;  Ipilimumab, with or without a gp100 peptide 
vaccine, did improve overall survival in patients with previously treated metastatic melanoma. 3  
 Ipilimumab monotherapy showed a clear dose-dependent effect on biological and clinical 
variables in patients with advanced melanoma.  The best overall response rate was associated 
significantly with increasing dose of ipilimumab. 6  The studies chosen for analysis had several 
limitations, including statistical significance, sample size, drop-out rate, biased of funding.   Both 
the Hodi et al. and Weber et al. study lacking statistically significant p-values, limits the validity 
and accuracy of the data reported. 3,5   The small sample size of 113 in the Weber et al. research 
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and drop out rates as high as 40% in the Hodi et al. research restrict conclusions from data 
collected on this population. 3   A conflict of interest may be created by funding of all articles by 
Bristol-Myers Squibb, manufacturer of ipilimumab.  In addition, each of the three studies 
attempted to measure progression or overall survival, but using different means for assessment 
resulting in an inconsistency and difficulty in comparison.  Also lacking in continuity, were the 
experimental and control groups chosen, which varied in each study. 
CONCLUSIONS   
The studies reviewed illustrate an association between ipilimumab and improvement in overall 
survival of patients with previously treated metastatic melanoma. 3,5,6   However, the data is not 
sufficient to prove statistical significance of ipilimumab as an effective treatment for advanced 
melanoma.  The research is essentially inconclusive, without statistically significant p-values for 
all studies investigated, the most that can be confirmed is an association.  Continued research is 
needed to determine statistically significant relationship between ipilimumab as a treatment for 
metastatic melanoma.  Additionally, the optimal dosing and regimen for reducing adverse effects 
and maximizing efficacy, required further study.  Future research is desirable, particularly at a 
dose of 10 mg/kg ipilimumab.  Ideally, a systematic review able to compare multiple studies 
involving solely ipilimumab at optimal dosage to a control of a placebo consistent between all 
articles analyzed.  
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